

**Abstract - Presentation for the Workshop " Early Discovery of New Antibiotics"
Paris 12-13 January 2017**

Name of speaker:	Klaas Martinus Pos
Name of presentation:	Exploiting an old drug as a basis for inhibitory discovery



Abstract: Our JPI AMR working group includes academic and industry researchers with skills in medical microbiology, pharmacokinetics, structural biology, biochemistry, drug design, mathematics, and drug discovery/development. We organized a conference/network meeting and invited key experts in the treatment of UTIs and impact of AMR (including in the elderly), properties of the drug nitrofurantoin (clinical practice, medicinal chemistry, pharmacokinetics and pharmacology) and nitrofurantoin resistance, to cover experience from 'bench to bedside'. The delivery of the proposed network will be a consortium in the framework of H2020 or Marie Curie ITN that can provide both a new paradigm and a scientific basis of inhibitor discovery based on an old drug and that can be translated to drug development.